Literature DB >> 8298233

The significance of methicillin-resistant Staphylococcus aureus infection in general surgery: a multivariate analysis of risk factors and preventive approaches.

M Shimada1, T Kamakura, H Itasaka, T Matsumata, M Hashizume, K Sugimachi.   

Abstract

To investigate the characteristics, risk factors, and prevention of methicillin-resistant Staphylococcus aureus (MRSA), a total of 3,627 patients were studied. Among these, 1,336 patients with various infections were used in a risk factor analysis of MRSA to determine the relationship between the use of antibiotics and the incidence of MRSA. Only 3.0% of infections were attributed to MRSA, the esophagus and colorectal region being highly involved, as anastomotic or pelvic abscesses, while the lung had a lower incidence. Almost half the patients with MRSA infections (47.6%) had concomitant infection. A univariate analysis revealed the following significant factors: The coexistence of gastrointestinal or metastatic malignancy, sepsis, tracheostomy, and the prior use of antibiotics such as the beta-lactam compounds or aminoglycosides. A multivariate analysis showed that gastrointestinal malignancy, sepsis, and the prior use of aminoglycosides, tetracycline, macrolides, and carbapenems were independently significant factors. To promote the education of doctors and nurses, regular in-service meetings on MRSA were held in the ward. Moreover, preventive approaches such as patient isolation, strategically placed hand washing equipment, and the use of disposable gloves and contaminated waste bags, have been initiated, and the incidence of MRSA has decreased significantly since then. Thus, to control MRSA, the following steps should be taken: (1) constant and careful surveillance, (2) regular risk factor analyses, (3) the optimal administration of antibiotics, and (4) the education of all hospital staff.

Entities:  

Mesh:

Year:  1993        PMID: 8298233     DOI: 10.1007/BF00311366

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  7 in total

1.  [Methicillin-resistant Staphylococcus aureus (MRSA) infection--significance of MRSA in respiratory tract infection].

Authors:  Y Shigeno; T Yamashiro; N Kusano
Journal:  Rinsho Byori       Date:  1990-09

2.  Methicillin resistant Staphylococcus aureus: where are we now?

Authors:  D M Allen
Journal:  Singapore Med J       Date:  1991-02       Impact factor: 1.858

Review 3.  Methicillin-resistant Staphylococcus aureus.

Authors:  W Brumfitt; J Hamilton-Miller
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

4.  [Analysis of methicillin-cephem resistant Staphylococcus aureus (MRSA) hospital infection and toxigenicity of MRSA].

Authors:  M Takahashi; T Narisawa; H Kotanagi; Y Yamazaki; H Kusaka; K Koyama; O Nakagomi
Journal:  Nihon Geka Gakkai Zasshi       Date:  1990-10

5.  The international spread of methicillin-resistant Staphylococcus aureus.

Authors:  D E Townsend; N Ashdown; S Bolton; J Bradley; G Duckworth; E C Moorhouse; W B Grubb
Journal:  J Hosp Infect       Date:  1987-01       Impact factor: 3.926

Review 6.  Staphylococcus aureus. The persistent pathogen (first of two parts).

Authors:  J N Sheagren
Journal:  N Engl J Med       Date:  1984-05-24       Impact factor: 91.245

7.  Subinhibitory concentrations of imipenem induce increased resistance to methicillin and imipenem in vitro in methicillin-resistant Staphylococcus aureus.

Authors:  B A Forbes; K D McClatchey; D R Schaberg
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

  7 in total
  2 in total

1.  Methicillin-resistant Staphylococcus aureus infection in vascular surgical patients.

Authors:  G J Murphy; R Pararajasingam; A Nasim; M J Dennis; R D Sayers
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

2.  Methicillin-resistant Staphylococcus aureus in orthopaedic surgery.

Authors:  C C Tai; A A Nirvani; A Holmes; S P F Hughes
Journal:  Int Orthop       Date:  2003-09-05       Impact factor: 3.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.